$MDGL
Madrigal Pharmaceuticals Inc

2011 Q3 Form 10-Q Financial Statement

#000110465911060264 Filed on November 03, 2011

View on sec.gov

Income Statement

Concept 2011 Q3 2010 Q3
Revenue $521.0K $3.400M
YoY Change -84.68% -97.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.100M $2.600M
YoY Change 19.23% -16.13%
% of Gross Profit
Research & Development $10.75M $11.02M
YoY Change -2.47% 21.13%
% of Gross Profit
Depreciation & Amortization $400.0K $470.0K
YoY Change -14.89% -22.95%
% of Gross Profit
Operating Expenses $13.88M $13.61M
YoY Change 1.97% 11.59%
Operating Profit -$12.22M -$10.23M
YoY Change 19.42%
Interest Expense -$516.0K -$31.00K
YoY Change 1564.52% -69.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.70M -$10.30M
YoY Change 23.3% -108.72%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.70M -$10.30M
YoY Change 23.3% -108.72%
Net Earnings / Revenue -2437.62% -302.94%
Basic Earnings Per Share
Diluted Earnings Per Share -$9.071M -$8.583M
COMMON SHARES
Basic Shares Outstanding 49.50M shares 40.38M shares
Diluted Shares Outstanding 40.38M shares

Balance Sheet

Concept 2011 Q3 2010 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.70M $54.10M
YoY Change -6.28% 4.64%
Cash & Equivalents $20.60M $34.91M
Short-Term Investments $30.00M $19.20M
Other Short-Term Assets $1.400M $700.0K
YoY Change 100.0% -41.67%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $52.02M $54.80M
YoY Change -5.07% 3.59%
LONG-TERM ASSETS
Property, Plant & Equipment $1.300M $2.600M
YoY Change -50.0% -43.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $500.0K
YoY Change 0.0% 400.0%
Total Long-Term Assets $1.846M $3.100M
YoY Change -40.45% -34.04%
TOTAL ASSETS
Total Short-Term Assets $52.02M $54.80M
Total Long-Term Assets $1.846M $3.100M
Total Assets $53.87M $57.90M
YoY Change -6.96% 0.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.900M $2.400M
YoY Change 20.83% -46.67%
Accrued Expenses $6.300M $6.000M
YoY Change 5.0% -14.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.700M
YoY Change -100.0%
Long-Term Debt Due $4.600M $300.0K
YoY Change 1433.33% -78.57%
Total Short-Term Liabilities $17.12M $14.90M
YoY Change 14.87% -16.29%
LONG-TERM LIABILITIES
Long-Term Debt $12.20M $13.40M
YoY Change -8.96% 1118.18%
Other Long-Term Liabilities $0.00 $3.300M
YoY Change -100.0% -58.23%
Total Long-Term Liabilities $12.17M $16.70M
YoY Change -27.12% 85.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.12M $14.90M
Total Long-Term Liabilities $12.17M $16.70M
Total Liabilities $29.29M $31.60M
YoY Change -7.32% 18.35%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.60M $26.30M
YoY Change
Total Liabilities & Shareholders Equity $53.87M $57.90M
YoY Change -6.96% 0.52%

Cashflow Statement

Concept 2011 Q3 2010 Q3
OPERATING ACTIVITIES
Net Income -$12.70M -$10.30M
YoY Change 23.3% -108.72%
Depreciation, Depletion And Amortization $400.0K $470.0K
YoY Change -14.89% -22.95%
Cash From Operating Activities -$11.82M -$8.430M
YoY Change 40.21% 2.18%
INVESTING ACTIVITIES
Capital Expenditures -$260.0K -$70.00K
YoY Change 271.43% 133.33%
Acquisitions
YoY Change
Other Investing Activities $6.970M -$13.16M
YoY Change -152.96% -212.48%
Cash From Investing Activities $6.710M -$13.23M
YoY Change -150.72% -213.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -130.0K 13.96M
YoY Change -100.93% -2837.25%
NET CHANGE
Cash From Operating Activities -11.82M -8.430M
Cash From Investing Activities 6.710M -13.23M
Cash From Financing Activities -130.0K 13.96M
Net Change In Cash -5.240M -7.700M
YoY Change -31.95% -363.7%
FREE CASH FLOW
Cash From Operating Activities -$11.82M -$8.430M
Capital Expenditures -$260.0K -$70.00K
Free Cash Flow -$11.56M -$8.360M
YoY Change 38.28% 1.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
109000 USD
dei Amendment Flag
AmendmentFlag
false
us-gaap Interest Paid
InterestPaid
1464000 USD
CY2011Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53868000 USD
CY2011Q3 us-gaap Liabilities
Liabilities
29287000 USD
CY2011Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
12171000 USD
CY2011Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17116000 USD
CY2011Q3 us-gaap Assets
Assets
53868000 USD
CY2011Q3 us-gaap Assets Current
AssetsCurrent
52022000 USD
CY2010Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54067000 USD
CY2010Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-351050000 USD
CY2010Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000 USD
CY2010Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
374528000 USD
CY2010Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2010Q4 us-gaap Liabilities
Liabilities
30588000 USD
CY2010Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
13852000 USD
CY2010Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
11667000 USD
CY2010Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2159000 USD
CY2010Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
26000 USD
CY2010Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16736000 USD
CY2010Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
3333000 USD
CY2010Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4572000 USD
CY2010Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
201000 USD
CY2010Q4 snta Accrued Liabilities Current Excluding Accrued Contract Research Costs
AccruedLiabilitiesCurrentExcludingAccruedContractResearchCosts
4194000 USD
CY2010Q4 snta Accrued Contract Research Costs
AccruedContractResearchCosts
2511000 USD
CY2010Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1925000 USD
CY2010Q4 us-gaap Assets
Assets
54067000 USD
CY2010Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
366000 USD
CY2010Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2181000 USD
CY2010Q4 us-gaap Assets Current
AssetsCurrent
51520000 USD
CY2010Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
431000 USD
CY2010Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
116000 USD
CY2010Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
19663000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31310000 USD
CY2010Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42090205 shares
CY2010Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42090205 shares
CY2011Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49498350 shares
CY2011Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49498350 shares
CY2010Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2011Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2010Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2010Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2010Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2010Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2010Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
13882000 USD
CY2011Q3 snta Total Revenues
TotalRevenues
1664000 USD
CY2011Q3 snta Collaborative Revenues
CollaborativeRevenues
1143000 USD
CY2010Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40382862 shares
CY2010Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40382862 shares
CY2010Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2010Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-31000 USD
CY2010Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10231000 USD
CY2010Q3 us-gaap Operating Expenses
OperatingExpenses
13614000 USD
CY2010Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2591000 USD
CY2010Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11023000 USD
CY2010Q3 snta Total Revenues
TotalRevenues
3383000 USD
CY2010Q3 snta Collaborative Revenues
CollaborativeRevenues
3383000 USD
CY2010Q3 snta Cost Sharing Reimbursements
CostSharingReimbursements
2240000 USD
CY2010Q3 snta License And Milestone Revenues
LicenseAndMilestoneRevenues
1143000 USD
us-gaap Operating Expenses
OperatingExpenses
39354000 USD
snta Total Revenues
TotalRevenues
4161000 USD
snta Collaborative Revenues
CollaborativeRevenues
3429000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40062453 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40062453 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-111000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-28533000 USD
us-gaap Operating Expenses
OperatingExpenses
39299000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8393000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
30906000 USD
CY2010Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34906000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1747000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
15000000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
26807000 USD
snta Total Revenues
TotalRevenues
10766000 USD
snta Collaborative Revenues
CollaborativeRevenues
10766000 USD
snta Cost Sharing Reimbursements
CostSharingReimbursements
7337000 USD
snta License And Milestone Revenues
LicenseAndMilestoneRevenues
3429000 USD
dei Document Period End Date
DocumentPeriodEndDate
2011-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001157601
dei Entity Registrant Name
EntityRegistrantName
SYNTA PHARMACEUTICALS CORP
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
19213000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3504000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1191000 USD
snta Increase Decrease Accrued Contract And Research Costs
IncreaseDecreaseAccruedContractAndResearchCosts
627000 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1564000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
103000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
74000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
189000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1470000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3185000 USD
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
233000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
36644000 USD
us-gaap Nature Of Operations
NatureOfOperations
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2">(1)&nbsp;Nature of Business</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">Synta Pharmaceuticals Corp. (the Company) was incorporated in March&nbsp;2000 and commenced operations in July&nbsp;2001. The Company is a biopharmaceutical company focusing on discovering, developing and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">&nbsp;</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2">The Company is subject to risks common to emerging companies in the drug development and pharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, dependence on key personnel, uncertainty of market acceptance of products, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing and compliance with the U.S. Food and Drug Administration and other government regulations.</font></p></td></tr></table>
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2011
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31

Files In Submission

Name View Source Status
0001104659-11-060264-index-headers.html Edgar Link pending
0001104659-11-060264-index.html Edgar Link pending
0001104659-11-060264.txt Edgar Link pending
0001104659-11-060264-xbrl.zip Edgar Link pending
a11-25838_110q.htm Edgar Link pending
a11-25838_1ex31d1.htm Edgar Link pending
a11-25838_1ex31d2.htm Edgar Link pending
a11-25838_1ex32d1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snta-20110930.xml Edgar Link completed
snta-20110930.xsd Edgar Link pending
snta-20110930_cal.xml Edgar Link unprocessable
snta-20110930_def.xml Edgar Link unprocessable
snta-20110930_lab.xml Edgar Link unprocessable
snta-20110930_pre.xml Edgar Link unprocessable